Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 7/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25969253 | 0.82 | TSHR (0.50) | HTR3ACNR1CNR2ELANEF2 | |
| SCHEMBL15759320 | 0.82 | CNR1 (0.53) | HTR3ACNR1CNR2PARP1GLS | |
| SCHEMBL21413147 | 0.82 | KDM4C (0.41) | CFDSCN5ASCN9APLK1 | |
| SCHEMBL14777070 | 0.81 | CFD (0.38) | HTR3ACNR1CNR2ELANECFD | |
| SCHEMBL29805307 | 0.77 | ELANE (0.52) | HTR3ACNR1CNR2ELANEF2 | |
| SCHEMBL20534563 | 0.75 | PTGER4 (0.44) | CNR1CNR2PTGER4 | |
| SCHEMBL28144968 | 0.74 | HSD17B10 (0.58) | PARP1ELANE | |
| SCHEMBL20535137 | 0.74 | LMNA (0.41) | CNR1PTGER4 | |
| SCHEMBL14853611 | 0.74 | CNR1 (0.59) | CNR1CNR2PTGER4 | |
| SCHEMBL4246698 | 0.74 | BUB1 (0.43) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373317-B1 | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
| WO-2010065275-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE2A, GUCY1A2, PDE3A | HTR3A 2873/4885CNR1 1138/4885CNR2 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.